The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II randomized trial of talimogene laherparepvec (T-VEC) oncolytic immunotherapy with or without radiotherapy for patients with cutaneous metastases from solid tumors.
 
Christopher A. Barker
Consulting or Advisory Role - Regeneron
Research Funding - Alpha TAU Medical (Inst); Amgen (Inst); Elekta (Inst); EMD Serono (Inst); PSI (Inst); Regeneron (Inst)
(OPTIONAL) Uncompensated Relationships - Castle Biosciences
 
Sandra P. D'Angelo
Honoraria - Adaptimmune; GlaxoSmithKline; Pfizer; Rain Therapeutics; SERVIER
Consulting or Advisory Role - Adaptimmune; GlaxoSmithKline; Nektar; Pfizer; Rain Therapeutics; Rain Therapeutics; Servier
 
Alexa M. Steckler
Employment - Memorial Sloan-Kettering Cancer Center
 
Ming Lian
No Relationships to Disclose
 
Gloria Wasilewski
No Relationships to Disclose
 
Mario E. Lacouture
Stock and Other Ownership Interests - Oncoderm (I)
Honoraria - Apricity Health; AstraZeneca; Deciphera; Hoth Therapeutics; Incyte; Innovaderm; Janssen; Kinnate Biopharma; Kintara Therapeutics; Kintara Therapeutics; L'Oreal; La Roche-Posay; Loxo; Lutris; MJH Associates; Nanology; Novartis; Novocure; OnQuality Pharmaceuticals; RBC consultants; Relay Therapeutics; Repare Therapeutics; Roche/Genentech; Seagen; Seattle Genetics/Astellas; Trifecta; Tyra Biosciences
Consulting or Advisory Role - Apricity Health; AstraZeneca; Deciphera; Genentech; Incyte; Innovaderm; Janssen Research & Development; Kinnate Biopharma; Kintara Therapeutics; Kintara Therapeutics; La Roche-Posay; Loxo; Loxo; Lutris; Novartis; Novocure; OnQuality Pharmaceuticals; Relay Therapeutics; Repare Therapeutics; Repare Therapeutics; Roche; Roche; Seagen; Tyra Biosciences
Research Funding - AstraZeneca/MedImmune (Inst); Columbia University (Inst); Lutris (Inst); Lutris (Inst); National Jewish Health (Inst); Novartis (Inst); novocure (Inst); novocure (Inst); OnQuality Pharmaceuticals; OnQuality Pharmaceuticals (Inst); Paxman (Inst)
Other Relationship - Oncoderm (I)
(OPTIONAL) Uncompensated Relationships - Oncoderm
 
Paul B. Chapman
Stock and Other Ownership Interests - Rgenix
Consulting or Advisory Role - Black Diamond Therapeutics; GigaGen; Merck; Pfizer
Research Funding - Genentech; GigaGen; Merck; NCI (Inst); Pfizer
 
Alexander Noor Shoushtari
Consulting or Advisory Role - Bristol-Myers Squibb; Immunocore; Novartis
Research Funding - Bristol-Myers Squibb; Checkmate Pharmaceuticals (Inst); Foghorn Therapeutics (Inst); Immunocore; Linnaeus Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Polaris; Targovax (Inst); Xcovery
Patents, Royalties, Other Intellectual Property - UpToDate
 
Charlotte Eielson Ariyan
Employment - Pfizer (I)
Stock and Other Ownership Interests - Pfizer (I)
Consulting or Advisory Role - Iovance Biotherapeutics; Merck
Speakers' Bureau - Bristol-Myers Squibb